SCHEMBL1508012

SCHEMBL1508012

CCOP(=O)(O)C(c1ccc(F)cc1)(c1ccc(F)cc1)c1ccccc1F

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 7/20 0.47
KCNE1 P15382 1/20 0.45
KCNQ1 P51787 1/20 0.45
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 2/20 0.38
KMT2A Q03164 2/20 0.36
NR1I2 O75469 1/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 2/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1508149 0.90 KCNN4 (0.41) KCNN4KCNE1KCNQ1ALDH1A1KDM4E
SCHEMBL1507955 0.85 ALDH1A1 (0.42) KCNN4ALDH1A1KDM4EKMT2ANR1I2
SCHEMBL1508229 0.79 KCNN4 (0.53) KCNN4KCNE1KCNQ1NR1I2
SCHEMBL1508255 0.79 KMT2A (0.42) ALDH1A1KDM4EKMT2ANR1I2LMNA
SCHEMBL1507930 0.78 KCNN4 (0.40) KCNN4KCNE1KCNQ1ALDH1A1KDM4E
SCHEMBL1508218 0.78 KCNN4 (0.47) KCNN4ALDH1A1KDM4EKMT2ALMNA
SCHEMBL1508095 0.78 HDAC6 (0.40) ALDH1A1KDM4EKMT2AMEN1
SCHEMBL1508011 0.76 KCNN4 (0.45) KCNN4KCNE1KCNQ1KMT2ANR1I2
SCHEMBL6622435 0.72 KCNN4 (0.46) KCNN4KCNE1KCNQ1NR1I2GAA
SCHEMBL1507922 0.72 ALOX15 (0.38) ALDH1A1KMT2ALMNAMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP claimed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US claimed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP claimed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US claimed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US claimed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP claimed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO claimed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US disclosed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP disclosed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009816-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 KCNN4 48/4885KCNE1 29/4885KCNQ1 2/4885
US-20070161607-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 KCNN4 48/4885KCNE1 29/4885KCNQ1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.